Publications by authors named "Hunter Lambert"
Despite numerous available antiemetics, chemotherapy induced nausea and vomiting (CINV) still affects many patients, and CINV related hospitalizations and costs often result. PrecisionQ analyzed its database to evaluate CINV related hospitalizations and costs following antiemetics use including netupitant/fosnetupitant with palonosetron (NEPA), aprepitant/fosaprepitant with ondansetron (APON) or aprepitant/fosaprepitant with palonosetron (APPA) in patients receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy. Database analysis identified 15,583 patient records (807 NEPA, 2023 APON, 12,753 APPA) and mean CINV related hospitalization costs were lower across all patients receiving NEPA (US$301) compared with patients receiving APON ($1006, p < 0.
View Article and Find Full Text PDFArticle Synopsis
- - The use of daratumumab has improved outcomes for multiple myeloma patients, but community oncologists are often administering it more frequently than the FDA guidelines suggest.
- - A study analyzed treatment patterns and found that 65% of patients continued on daratumumab at week 24, with 330 patients receiving doses more often than the recommended once every four weeks.
- - The increased frequency of daratumumab administration resulted in an average of 14% more doses, leading to an estimated additional cost of $31,353 per year for patients.